That’s been the question floating around ResMed’s (ASX:RMD) HQ for the past five years, given its obstructive sleep apnea (OSA) therapy rival’s absence from the US device market owing to a product ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. ResMed (RMD) is back in focus after reporting higher sales and net income for ...

ResMed NASDAQ:RMD Chairman and CEO Michael J. Farrell sold 4,991 shares of company stock on February 9, 2026, for approximately $1.36 million. The sales were executed at a weighted average price of ...

ResMed shares have since risen to $271.56, representing a 8.1% premium to Farrell’s selling price. The medical equipment manufacturer currently has a market capitalization of $39.57 billion and trades ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. ResMed (NYSE:RMD) is seeing growing use of wearable devices for sleep apnea pre ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

Sydney: Sleep-breathing device maker ResMed plans to take global a doctor ‍education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, ⁠calling ...